



Ranbaxy Europe Limited
Indian Format Financial Statements
FY 2016 – 2017
1 April 2016 – 31 March 2017

VALIA & TIMBADIA CHARTERED ACCOUNTANTS	Tel: Off: 2269 2624 / 2269 9664/40040216 E-mail: valtim09@gmail.com 32, Trinity Chambers, 117, Bora Bazar Street, Fort, Mumbai – 400 001.
ARVIND P. VALIA B.COM. (Hons.), F.C.A. HITEN C. TIMBADIA B.COM. L.L.B. (GEN), F.C.A.	

INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF RANBAXY EUROPE LIMITED

Report on the Financial Statements

We have audited the accompanying Ind AS Financial Statements of **RANBAXY EUROPE LIMITED** (the "Company"), which comprise the Balance Sheet as at March 31, 2017 and the Statement of Profit and Loss (including other Comprehensive income), the statement of Cash Flows and Statement of Changes in Equity for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Management of the Company is responsible for the preparation of these financial statements that give a true and fair view of the financial position and financial performance of the Company in accordance with the Accounting Standards and Accounting Principles generally accepted in India. The responsibility includes the design, implementation and maintenance of adequate internal financial controls, that are operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation and fair presentation of the financial statements, in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Management of the Company, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion these financial statements.

VALIA & TIMBADIA
CHARTERED ACCOUNTANTS

ARVIND P. VALIA
B.COM. (Hons.), F.C.A.
HITEN C. TIMBADIA
B.COM. L.L.B. (GEN), F.C.A.

Tel: Off: 2269 2624 / 2269 9664/40040216
E-mail: valtim09@gmail.com
32, Trinity Chambers,
117, Bora Bazar Street, Fort,
Mumbai – 400 001.

Emphasis of Matters

The Company has made decision to cease the trading and accordingly transferred all the assets and liabilities of the business to the fellow subsidiary during the year 2016-17. The company has decided to go into liquidation soon, the Financial Statements have been prepared on a break up basis and not on a going concern basis.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India of the financial position of the Company as at 31 March, 2017, and its financial performance including other comprehensive income, its cash flows and the changes in equity for the year ended on that date.

FOR VALIA AND TIMBADIA
CHARTERED ACCOUNTANTS
(Firm Registration No. 112241W)

HITEN C. TIMBADIA
Partner
Membership No. 038429.

PLACE: MUMBAI
DATED: 10TH May, 2017

RANBAXY EUROPE LIMITED
BALANCE SHEET AS AT MARCH 31, 2017

in GBP

	Notes	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
ASSETS				
Non-current assets				
Property, plant and equipment	1	-	-	52.638
Investments in associates	2	-	6	6
Deferred tax asset, net	3	-	-	30.525
Total non-current assets		-	6	83.169
Current assets				
Financial assets				
Trade receivables	4	22.228	652.799	1.610.116
Cash and cash equivalents	5	1.809.471	1.618.251	1.035.928
Other financial assets	6	-	107.712	114.437
Other current assets	7	-	-	203.869
Total current assets		1.831.699	2.378.762	2.964.350
TOTAL ASSETS		1.831.699	2.378.768	3.047.519
EQUITY AND LIABILITIES				
Equity				
Equity share capital	8	10.000	10.000	10.000
Share application money pending allotment		-	-	-
Other equity		1.820.949	1.821.237	1.662.313
Total equity		1.830.949	1.831.237	1.672.313
Current liabilities				
Financial liabilities				
Trade payables	9	-	518.728	822.182
Other financial liabilities	10	-	-	135.955
Provisions	11	750	12.847	88.162
Other current liabilities	12	-	15.957	328.907
Total current liabilities		750	547.531	1.375.206
TOTAL EQUITY AND LIABILITIES		1.831.699	2.378.768	3.047.519
		-	-	(0)

See accompanying notes to the financial statements

In terms of our report of even date attached
For Valia & Timbadia
Chartered Accountants

For and on behalf of the Board

Hiten C Timbadia
Partner

Prashant Savla
Director

Date: 10th of may 2017

Date: 8th of may 2017

Place: Mumbai, India

Place: Hoofddorp, The Netherlands

RANBAXY EUROPE LIMITED
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2017

in GBP

	Notes	Year ended 31-mrt-17	Year ended 31-mrt-16
Revenue from operations	13	-	2.851.952
Other income	14	-	19.238
Total income		-	2.871.189
Expenses			
Employee benefits expense	15	-	1.942.315
Finance costs	16	1.243	-
Depreciation and amortisation expense	1		28.185
Other expenses	17	11.665	678.113
Total expenses		12.908	2.648.613
Profit/Loss before exceptional item and tax		(12.908)	222.576
Profit/Loss before tax		(12.908)	222.576
Tax expenses			
Current tax	18	(12.620)	33.127
Deferred tax	18		30.525
Loss for the year		(288)	158.924
Total comprehensive loss for the year		(288)	158.924

Earnings per equity share (face value per equity shares - ` 1)

Basic (in `)

Diluted (in `)

See accompanying notes to the financial statements

In terms of our report of even date attached

For Valia & Timbadia
Chartered Accountants

For and on behalf of the Board

Hiten C Timbadia
 Partner

Prashant Savla
 Director

Date: 10th of may 2017

Date: 8th of may 2017

Place: Mumbai, India

Place: Hoofddorp, The Netherlands

RANBAXY EUROPE LIMITED
CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2017

PARTICULARS	FOR THE YEAR ENDED 31.03.2017 Amount in GBP		FOR THE YEAR ENDED 31.03.2016 Amount in GBP	
A) Cash flow From Operating Activities				
Net Profit Before Tax	(288)	(288)	158.924	158.924
<u>Adjustments for</u>				
Profit on sale of Investment				
Other Income (Interest and investment income)				
Interest Expenses				
Operating (Loss) / Profit before Working Capital change				
Changes in working capital				
<i>Adjustments for (increase) / decrease in operating assets:</i>			83.163	
Decrease / (Increase) in Sundry Debtors	630.572		957.317	
Decrease / (Increase) in Loans and Advances/Other Assets	107.712		210.594	
<i>Adjustments for increase / (decrease) in operating liabilities:</i>			(388.266)	
(Decrease) / Increase - Trade & Other payables	(518.728)		(439.410)	
Income Tax paid				
Net Cash Flows from Operating Activities		191.502		423.398
B) Cash Flow from Investing Activities				
Decrease / (Increase) in Non-Current Investments	6			
Decrease / (Increase) in Current Investments				
Interest and investment income				
Decrease / (Increase) in Other Receivables				
Other Non-Operating Income				
Net Cash Flows from Investing Activities		6		-
C) Cash Flow from Financing Activities				
Decrease / (Increase) in Loans and Advances				
Proceeds from issue of Equity Shares				
Interest Income				
Increase / (Decrease) in Long Term Borrowings				
Interest Expenses				
Increase / (Decrease) in Short Term Borrowings				
Net Cash Flows from Financing Activities		-		-
Net Increase / (Decrease) in Cash & Cash equivalents		191.220		582.322
Cash & Cash Equivalents at Beginning of the year	1.618.251		1.035.928	
Cash & Cash Equivalents at the End of the Year	1.809.471		1.618.251	

Note : Cash & Cash Equivalents Consist of the cash /cheque in hand & bank balance in current Account.

In terms of our report of even date attached

For Valia & Timbadia
Chartered Accountants

For and on behalf of the Board

Hiten C Timbadia
Partner

Prashant Savla
Director

Date: 10th of may 2017

Date: 8th of may 2017

Place: Mumbai, India

Place: Hoofddorp, The Netherlands

RANBAXY EUROPE LIMITED
NOTES FORMING PART OF FINANCIAL STATEMENTS AS AT AND FOR YEAR ENDED MARCH 31,

NOTE : 1

PROPERTY, PLANT AND EQUIPMENT

in GBP

	Office equipment	Furniture and fixtures	Total
At cost / deemed cost			
As at April 1, 2015	305.118	452.706	757.824
Additions			-
Disposals	(305.118)	(452.706)	(757.824)
Transfers			-
As at March 31, 2016	-	-	-
Additions			-
Disposals			-
Transfers			-
As at March 31, 2017	-	-	-
Accumulated depreciation and impairment			
As at April 1, 2015	273.032	432.155	705.186
Depreciation expense	7.714	20.471	28.185
Impairment loss			-
Disposals	(280.745)	(452.626)	(733.371)
As at March 31, 2016	-	-	-
Depreciation expense			-
Impairment loss			-
Disposals			-
As at March 31, 2017	-	-	-
Carrying value			
As at April 1, 2015	32.086	20.551	52.638
As at March 31, 2016	-	-	-
As at March 31, 2017	-	-	-

RANBAXY EUROPE LIMITED
 NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2017

NOTE : 2
 INVESTMENTS IN ASSOCIATES

	As at 31-mrt-17		As at 31-mrt-16		As at 1-apr-15	
	Qty.	in GBP	Qty.	in GBP	Qty.	in GBP
Quoted - equity shares (At cost) Zenotech Laboratories Limited Shares of ` 10 each fully paid Less : amount of impairment in value of investments						
Un-quoted - equity shares (At cost) Daichi Sankyo (Thailand) Limited Ordinary Shares of Bahts 100 each fully paid	-	-	1	6,0	1	6,0
Total investment in associates		-		6,00		6,0

RANBAXY EUROPE LIMITED
 NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2017

NOTE : 3
 DEFERRED TAX ASSETS (NET)

	Opening balance April 01, 2015	Recognised in profit and loss statement	Recognised in other comprehensive income	Recognised directly in equity	Reclassified from equity to profit or loss	Closing balance March 31, 2016
Property plant and equipment	11,246	11,246				
Provisions	19,279					
	30,525	11,246	-	-	-	-

NOTE : 4
 TRADE RECEIVABLES

	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
Current			
Unsecured considered good - from related parties	22,228	652,799	1,610,116
	22,228	652,799	1,610,116

NOTE : 5
 CASH AND CASH EQUIVALENTS

	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
Balances with banks			
In current accounts	1,809,471	1,618,251	1,035,928
	1,809,471	1,618,251	1,035,928

NOTE : 6
 OTHER CURRENT FINANCIAL ASSETS

	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
Unsecured considered good unless stated otherwise			
Amortised cost			
Security deposits		100,716	114,437
Other receivables		6,996	
	-	107,712	114,437

NOTE : 7
 OTHER CURRENT ASSETS

	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
Unsecured considered good unless stated otherwise			
Prepaid expenses	-		197,307
Other assets	-		6,562
	-	-	203,869

NOTE : 8
 EQUITY SHARE CAPITAL

	As at 31-mrt-17		As at 31-mrt-16		As at 1-apr-15	
	No. of shares	in GBP	No. of shares	in GBP	No. of shares	in GBP
Authorised						
Equity shares of £ 1 each						
Cumulative preference shares of £ 100 each						
	-	-	-	-	-	-
Issued, subscribed and fully paid up						
Equity Shares of £ 1 each		10,000		10,000		10,000
	-	10,000	-	10,000	-	10,000

RANBAXY EUROPE LIMITED
NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2017

	As at 31-mrt-17		As at 31-mrt-16			
	No. of shares	in GBP	No. of shares	in GBP		
Reconciliation of fully paid equity shares						
Opening balance						
Add : shares allotted during the year pursuant to the scheme of amalgamation						
Add : shares allotted to employees on exercise of employee stock option (excluding shares held by ESOP trust)						
Less : buy back of shares						
Closing balance	-	-	-	-		
Details of shareholders holding more than 5% in the Company						
	As at 31-mrt-17		As at 31-mrt-16		As at 1-apr-15	
Equity shares	No. of shares	% of holding	No. of shares	% of holding	No. of shares	% of holding
Ranbaxy Holdings (UK) Ltd.	10.000	100				

NOTE : 9
TRADE PAYABLES

	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
Trade payables to related parties	-	515.760	440.088
Others	-	2.968	382.084
	-	518.728	822.182

NOTE : 10
OTHER CURRENT FINANCIAL LIABILITIES

	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
At amortised cost			
Others			135.955
	-	-	135.955

NOTE : 11
SHORT TERM PROVISIONS

	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
Employee Benefits			46.442
Others	750	12.847	41.720
	750	12.847	88.162

NOTE : 12
OTHER CURRENT LIABILITIES

	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
Statutory remittances		15.957	253.570
Others			75.337
	-	15.957	328.907

RANBAXY EUROPE LIMITED
NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2017

NOTE : 13
REVENUE FROM OPERATIONS

	in GBP	
	Year ended 31-mrt-17	Year ended 31-mrt-16
Sale of products (including excise duty) Other operating revenues		2,851,952
	-	2,851,952

NOTE : 14
OTHER INCOME

	in GBP	
	Year ended 31-mrt-17	Year ended 31-mrt-16
Other non-operating income (net of expenses directly attributable to such income) Miscellaneous income		19,238
	-	19,238

NOTE : 15
EMPLOYEE BENEFITS EXPENSE

	in GBP	
	Year ended 31-mrt-17	Year ended 31-mrt-16
Salaries and wages Contribution to provident and other funds Staff welfare expenses		1,719,222 191,078 32,015
	-	1,942,315

NOTE : 16
FINANCE COSTS

	in GBP	
	Year ended 31-mrt-17	Year ended 31-mrt-16
Interest expense on borrowing and others	1,243	
	1,243	-

NOTE : 17
OTHER EXPENSES

	in GBP	
	Year ended 31-mrt-17	Year ended 31-mrt-16
Power and fuel		14,177
Rent	-	115,331
Rates and taxes		30,164
Insurance		12,639
Others	-	34,631
Printing and stationery		8,328
Travelling and conveyance		58,335
Communication		35,195
Professional, legal and consultancy	1,100	377,887
Net (gain) / loss on foreign currency transactions and translation	5,710	(72,647)
As auditors	750	4,375
Miscellaneous expenses	4,105	59,699
	11,665	678,113
Less : Receipts from Research Activities		
	11,665	678,113

RANBAXY EUROPE LIMITED
 NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2017

NOTE : 18
 TAX RECONCILIATION

	in GBP	
	Year ended 31-mrt-17	Year ended 31-mrt-16
Reconciliation of current tax expense		
Profit before tax	(12.908)	222.576
Enacted income tax rate (%)		
Tax expense	(12.620)	33.127
Others		30.525
	(12.620)	63.652
Income tax expense recognised in profit and loss	(12.620)	63.652

RANBAXY EUROPE LIMITED
NOTES FORMING PART OF FINANCIAL STATEMENTS AS AT AND FOR YEAR ENDED MARCH 31, 2017

NOTE : 19

(A) ACCOUNTING POLICIES :

1. Basis of Accounting

The Company has prepared financial statements for the year ended March 31, 2017 in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 together with the comparative period data as at and for the year ended March 31, 2016. Further, the Company has prepared the opening balance sheet as at April 1, 2015 (the transition date) in accordance with Ind AS.

Upto the year ended March 31, 2016, the company prepared its financial statements in accordance with the requirements of previous GAAP, which includes Standards notified under the Companies (Accounting Standards) Rules, 2006 (as amended).

The Company has made the decision to cease trading and accordingly transferred all assets and liabilities of the business to a fellow subsidiary during the year 2016-17. As the Company is insolvent and decided to go into liquidation soon, financial statements are prepared on a break-up basis and not on a going concern basis.

2. Financial Assets

i. Initial recognition and measurement

All financial assets are recognised initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognised on the trade date.

ii. Subsequent measurement

For purposes of subsequent measurement, financial assets are classified in four categories:

- Debt instruments at amortised cost
- Debt instruments at fair value through other comprehensive income (FVTOCI)
- Debt instruments and equity instruments at fair value through profit or loss (FVTPL)
- Equity instruments measured at fair value through other comprehensive income (FVTOCI)

iii. Debt instruments at amortised cost

A 'debt instrument' is measured at the amortised cost if both the following conditions are met:

- a) The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- b) Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding

This category is the most relevant to the Group. After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in Other Income in the profit or loss. The losses arising from impairment are recognised in the profit or loss.

iv. Debt instrument at FVTPL

FVTPL is a residual category for debt instruments. Any debt instrument, which does not meet the criteria for categorization as at amortized cost or as FVTOCI, is classified as at FVTPL.

In addition, the group may elect to designate a debt instrument, which otherwise meets amortized cost or FVTOCI criteria, as at FVTPL. However, such election is allowed only if doing so reduces or eliminates a measurement or recognition inconsistency (referred to as 'accounting mismatch'). The group has not designated any debt instrument as at FVTPL.

Debt instruments included within the FVTPL category are measured at fair value with all changes recognized in the profit or loss

v. Equity instruments

Equity instruments included within the FVTPL category are measured at fair value with all changes recognized in the profit or loss

3. Financial liabilities and equity instruments

Classification as debt or equity

Debt and equity instruments issued by a group entity are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument

a. Equity Instruments

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by a group entity are recognised at the proceeds received, net of direct issue costs.

b. Compound financial instruments

The component parts of compound financial instruments (convertible notes) issued by the Company are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument

i. Initial recognition and measurement

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

ii. Subsequent measurement

All financial liabilities are subsequently measured at amortised cost using the effective interest method or at FVTPL.

Financial liabilities at fair value through profit or loss

Financial liabilities are classified as at FVTPL when the financial liability is either contingent consideration recognised by the Group as an acquirer in a business combination to which Ind AS 103 applies or is held for trading or is designated upon initial recognition as at fair value through profit or loss. Financial liabilities are classified as held for trading if they are incurred principally for the purpose of repurchasing in the near term or on initial recognition it is part of a portfolio of identified financial instruments that the Group manages together and has a recent actual pattern of short-term profit-taking. This category also includes derivative entered into by the group that are not designated and effective as hedging instruments in hedge relationships as defined by Ind AS 109. Gains or losses on liabilities held for trading are recognised in the profit or loss.

Financial liabilities designated upon initial recognition at fair value through profit or loss are designated as such at the initial date of recognition, and only if the criteria in Ind AS 109 are satisfied. For non-held-for-trading financial liabilities designated as at FVTPL, fair value gains/ losses attributable to changes in own credit risk are recognized in OCI, unless the recognition of the effects of changes in the liability's credit risk in other comprehensive income would create or enlarge an accounting mismatch in profit or loss, in which case these effects of changes in credit risk are recognised in profit or loss. These gains/ loss are not subsequently transferred to profit or loss. All other changes in fair value of such liability are recognised in the statement of profit or loss. The group has not designated any financial liability as at fair value through profit and loss.

Financial liabilities subsequently measured at amortised cost

Financial liabilities that are not held-for-trading and are not designated as at FVTPL are measured at amortised cost at the end of subsequent accounting periods. The carrying amounts of financial liabilities that are subsequently measured at amortised cost are determined based on the effective interest method. Interest expense that is not capitalised as part of costs of an asset is included in the 'Finance costs' line item

4. Recognition of Revenue

Revenue is measured at the fair value of the consideration received or receivable.

a. Rendering Services

Revenue from services rendered is recognized in the profit or loss as the underlying services are performed. Upfront non-refundable payments received are deferred and recognized as revenue over the expected period over which the related services are expected to be performed.

b. Interest Income

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Group and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

c. Profit from Investments

Profit from Non Current Investments are calculated on the basis of FIFO method.
Profit from Current Investments are calculated on the basis of NAV.

5. Risk Management

The Company's activities are not exposed to any material financial risks including market risk, credit risk and liquidity risk.

5.a Accounting Standard (AS-20) on Earnings Per Share

	Year ended 31st March, 2017	Year ended 31st March, 2016
Profit for the year - used as Numerator for calculating Earnings Per Share	(288)	158.924
Weighted Average number of Shares used in computing Basic Earnings Per Share	10.000	10.000
Add: Dilution effect of Employee Stock Options	-	-
Weighted Average number of Shares used in computing Diluted Earnings Per Share	<u>10.000</u>	<u>10.000</u>
Nominal value per share (in Euro)	1	1
Basic Earnings Per Share (in Euro)	(0)	16
Diluted Earnings Per Share (in Euro)	(0)	16

5.b Related Party Transactions

	Year ended 31st March, 2017	Year ended 31st March, 2016
Other Income		
Ranbaxy (UK) Ltd	-	516.424
Laboratorios Ranbaxy S.L.	-	125.290
Basics GmbH	-	144.937
Ranbaxy Pharmacie Generiques SAS	-	194.523
Ranbaxy Italia SpA	-	105.540
Terapia SA	-	144.031
Ranbaxy Laboratorios Ltd	-	1.621.206
Purchase of Goods		
Interest Expense		
Other Expenses		
Terapia SA	-	226.206
Ranbaxy Poland Sp Zoo	-	18.374
Ranbaxy Laboratorios Ltd	-	41
Trade Receivables		
Ranbaxy (U.K.) Ltd.	-	626.776
Ranbaxy Holdings UK Limited	22.228	22.228
Ranbaxy Laboratorios Ltd	-	3.796
Loans Taken		
Trade Payable		
Ranbaxy (U.K.) Ltd.	-	515.760

6. Taxes on Income

Income tax expense consists of current and deferred tax. Income tax expense is recognized in profit or loss except to the extent that it relates to items recognized in other comprehensive income or directly in equity, in which case it is recognized in other comprehensive income or directly in equity respectively. Current tax is the expected tax payable on the taxable profit for the year, using tax rates enacted or substantively enacted by the end of the reporting period, and any adjustment to tax payable in respect of previous years.

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profits and taxable temporary differences arising upon the initial recognition of goodwill

Deferred tax is measured at the tax rates that are expected to be applied to the temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the end of the reporting period.

A deferred tax asset is recognized to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

7. Provisions, Contingent Liabilities and Contingent Assets

Provisions are recognised only when there is a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate of the amount of the obligation can be made. Contingent liability is disclosed for (i) Possible obligations which will be confirmed only by future events not wholly within the control of the Company or (ii) Present obligations arising from past events where it is not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount of the obligation cannot be made. Contingent Assets are not recognised in the financial statements.

8 Accounting policies not specifically mentioned above will be as per generally accepted accounting principles in India.

(B) First-time adoption of Ind-AS

These financial statements for the year ended March 31, 2017 have been prepared in accordance with Ind AS. For the purposes of transition to Ind AS, the Company has followed the guidance prescribed in Ind AS 101 - First Time adoption of Indian Accounting Standard, with April 1, 2015 as the transition date. The transition to Ind AS has resulted in changes in the presentation of the financial statements, disclosures in the notes thereto and accounting policies and principles. The accounting policies set out in Note A have been applied in preparing the standalone financial statements for the year ended March 31, 2017 and the comparative information.

In terms of our report of even date attached
For Valia & Timbadia
Chartered Accountants

For and on behalf of the Board

Hiten C Timbadia
Partner

Prashant Savla
Director

Date: 10th of may 2017

Date: 8th of may 2017

Place: Mumbai, India

Place: Hoofddorp, The Netherlands